Product licences for alemtuzumab and multiple sclerosis.

www.thelancet.com Vol 383 March 8, 2014 867 sexual violence that we did not ask about, which is a matter of regret. When designing the questionnaire, about 5 years ago, sexual violence had not fully come to the fore as a topic of public health importance and new questions were required to compete with a wide range of topics traditionally included in the survey. This is certainly a section of the survey that we will seek to develop for Natsal-4. We do not ask questions about sexual experiences at age 12 years or younger, whether consensual or otherwise, on the grounds that this is likely to be an overly sensitive area for (generalist) interviewers to deal with. Querying on the part of ethical review committees, even of questions probing sexual experience before 16 years of age, suggests that we would have had diffi culty in obtaining ethical approval had we sought to do so.